Anti hyperlipidemic activity of Tephrosia purpurea plant extracts in poloxomer 407 induced hyperlipidemic rats

Abstract

Aim & Objective: Screening Of Antihyperlipidemic Activity of Tephrosia purpurea Plant Extracts.Material & Method: Screening of antihyperlipidemic was done by using Tephrosia purpurea Leaves, Stem and Whole plant (except Leaves) extracts. Part extracts used for antihyperlipidemic activity were stem (500 mg/kg), leaves (400mg/kg) and whole plant extracts except leaves at the dose of (300mg/kg, 600mg/kg).Hyperlipidemia was administered in experimental animals using Poloxomer 407 by intraperitoneal administration at the dose of 1g/kg. Blood was withdrawn through retro orbital puncture at 15& 24 hrs intervals. Antihyperlipidemic activity of Tephrosia purpurea plant extracts were evaluated by estimation of lipid profiles.Results: Estimation of lipid profile shows that Tephrosia purpurea stem extract (500mg/kg), Tephrosia purpurea leaves extract (400mg/kg), Tephrosia purpurea whole plant extract (300mg/kg) shows the less significant antihyperlipidemic activity. While Tephrosia purpurea whole plant extract at the dose of 600mg/kg shows potent antihyperlipidemic activity. It decreases TC, TG, LDL, VLDL and increases HDL levels. Tephrosia purpurea whole plant extract 600 mg/kg shows significant antihyperlipidemic activity as standard drug Atorvastatin.Conclusion: Hydro methanolic extracts of Tephrosia purpurea whole plant inhibits cholesterol and triglycerides synthesis. Increasing in stimulation of lipolysis by lipoprotein lipase is responsible for plasma triglycerides hydrolysis. The elevation of serum cholesterol levels following i.p. injection of Poloxomer 407 solution to rats was due to stimulation of 3-hydroxy-3-rmethylglutaryl-Co-enzyme A (HMG-Co A) reductase activity in the liver by the Poloxomer. Hydro methanolic extract of Tephrosia purpurea Showed lowering of TG levels by increasing the lipoprotein lipase activities. The cholesterol lowering effect of Tephrosia purpurea extract were observed in rats treated with the Poloxomer 407 by the inhibition of HMG Co A reductase inhibition.